



Contacts: Tularik Inc.
Traci McCarty, 650/825-7182 (investors/media)

Tularik Appoints Jack M. Anthony to Senior Vice President, Business and Commercial Development

South San Francisco, Calif. –(BW HealthWire) – Nov. 18, 2002 – Tularik Inc. (Nasdaq:TLRK) today announced the appointment of industry veteran Jack M. Anthony as Senior Vice President, Business and Commercial Development. In his new position, Mr. Anthony will lead the Company's worldwide business development initiatives.

"One of the cornerstones of Tularik's business model has been the retention of rights to all products and project areas. This has resulted in a valuable portfolio of assets that can now be leveraged selectively to see us through to profitability," said David V. Goeddel, Ph.D., CEO of Tularik. "Jack will initiate and execute strategies to capitalize on these attractive opportunities, providing a catalyst for Tularik's growth."

Mr. Anthony added, "With great science and a sustainable pipeline, Tularik is well-positioned to enter into innovative and mutually rewarding collaborations with major pharmaceutical and biotech companies. I look forward to working with the Tularik team to accomplish our corporate development goals."

Mr. Anthony was formerly Vice President of Global Business Development at FibroGen, Inc. where his responsibilities included corporate strategy, pre-marketing and corporate development. During his tenure, he initiated and implemented research, development and commercialization agreements with global life sciences companies such as Aventis Pasteur, Sankyo Company, Ltd. and Taisho Pharmaceutical Co., Ltd. Prior to joining FibroGen, Mr. Anthony was the Executive Vice President of Marketing and Business Development at Cell Therapeutics, Inc. where he negotiated a worldwide development and commercialization agreement with Johnson & Johnson, among others. He also held senior business development and marketing positions at Inhale Therapeutic Systems, Inc. and Applied Immune Sciences, Inc., after having worked at Baxter Healthcare Corporation for nearly 18 years in various executive positions.

About Tularik

Tularik is engaged in the discovery and development of a broad range of novel and superior orally available medicines that act through the regulation of gene expression. Tularik's scientific platform is focused on three therapeutic areas: cancer, immunology and metabolic disease. The Company currently has three drug candidates in clinical trials. T67 is moving into a pivotal Phase 2/3 study for the treatment of Hepatocellular

Carcinoma (HCC) and T607 is in four Phase 2 trials for the treatment of HCC, non-Hodgkin's lymphoma, ovarian cancer and gastric cancer. T487, for the treatment of inflammatory diseases, is in a Phase 1 trial to evaluate safety. For more information, visit Tularik's Internet website at www.tularik.com.

This press release contains "forward-looking" statements. For this purpose, any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends" and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause the results of Tularik to differ materially from those indicated by these forward-looking statements, including, among others, risks detailed from time to time in Tularik's SEC reports, including the report on Form 10-Q for the quarter ended September 30, 2002 and the report on Form 10-K for the year ended December 31, 2001. Tularik does not undertake any obligation to update forward-looking statements.